Novosteo Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 18

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $16.5M

  • Investors
  • 1

Novosteo General Information

Description

Developer of a drug discovery platform designed to reduce the morbidity, mortality, and loss of productivity associated with bone fractures. The company's platform includes a series of fracture-targeted drugs that concentrate a drug's healing power specifically at the fracture site, thereby accelerating and improving the healing process, enabling patients to reduce the debilitating and often life-threatening effects of bone fractures.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1281 Win Hentschel Boulevard
  • Suite 1594
  • West Lafayette, IN 47906
  • United States
+1 (765)
Primary Industry
Pharmaceuticals
Vertical(s)
Corporate Office
  • 1281 Win Hentschel Boulevard
  • Suite 1594
  • West Lafayette, IN 47906
  • United States
+1 (765)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novosteo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 19-May-2022 $16.5M Completed Pre-Clinical Trials
7. Early Stage VC (Series A) 29-Dec-2021 Completed Pre-Clinical Trials
6. Grant 15-Sep-2019 Completed Pre-Clinical Trials
5. Seed Round 08-Aug-2019 Completed Pre-Clinical Trials
4. Seed Round 08-May-2019 Completed Pre-Clinical Trials
3. Seed Round 26-Dec-2018 Completed Pre-Clinical Trials
2. Grant 09-Oct-2018 $1.71M Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2017 Completed Startup
To view Novosteo’s complete valuation and funding history, request access »

Novosteo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to reduce the morbidity, mortality, and loss of productivity associated
Pharmaceuticals
West Lafayette, IN
18 As of 2022

Stockholm, Sweden
 

Mont-Saint-Guibert, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novosteo Competitors (16)

One of Novosteo’s 16 competitors is Synartro, a Venture Capital-Backed company based in Stockholm, Sweden.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Synartro Venture Capital-Backed Stockholm, Sweden
NOVADIP Venture Capital-Backed Mont-Saint-Guibert, Belgium
Bonesupport Formerly PE-Backed Lund, Sweden
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA
Arvinas Formerly VC-backed New Haven, CT
You’re viewing 5 of 16 competitors. Get the full list »

Novosteo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novosteo Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioCrossroads Venture Capital Minority
Elevate Ventures Venture Capital Minority
Kairos Ventures Venture Capital Minority
National Institute of Dental and Craniofacial Research Government
National Institutes of Health Government
You’re viewing 5 of 9 investors. Get the full list »

Novosteo FAQs

  • When was Novosteo founded?

    Novosteo was founded in 2017.

  • Where is Novosteo headquartered?

    Novosteo is headquartered in West Lafayette, IN.

  • What is the size of Novosteo?

    Novosteo has 18 total employees.

  • What industry is Novosteo in?

    Novosteo’s primary industry is Pharmaceuticals.

  • Is Novosteo a private or public company?

    Novosteo is a Private company.

  • What is the current valuation of Novosteo?

    The current valuation of Novosteo is .

  • What is Novosteo’s current revenue?

    The current revenue for Novosteo is .

  • How much funding has Novosteo raised over time?

    Novosteo has raised $18.5M.

  • Who are Novosteo’s investors?

    BioCrossroads, Elevate Ventures, Kairos Ventures, National Institute of Dental and Craniofacial Research, and National Institutes of Health are 5 of 9 investors who have invested in Novosteo.

  • Who are Novosteo’s competitors?

    Synartro, NOVADIP, Bonesupport, Dicerna Pharmaceuticals, and Arvinas are some of the 16 competitors of Novosteo.

  • When was Novosteo acquired?

    Novosteo was acquired on 19-May-2022.

  • Who acquired Novosteo?

    Novosteo was acquired by IRulya Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process